Aurobindo Pharma shares surged 2.68% to close at ₹1,590.70 from the previous day's ₹1,549.20, driven by strong quarterly results. The pharmaceutical major reported robust financial performance with total income growing 5.08% to ₹8,833.54 crore in Q3 FY26, compared to ₹8,406.29 crore in the same period last year. The company's profit after tax (PAT) jumped 34.13% to ₹1,138.01 crore from ₹848.45 crore year-on-year, demonstrating significant operational efficiency improvements. With a market capitalization of ₹91,525.36 crore, Aurobindo Pharma maintains its position as a large-cap pharmaceutical company within the sector.
According to The Economic Times, Aurobindo Pharma is exhibiting a strong bullish technical structure on the daily timeframe and is currently trading around ₹1,590. The stock continues to maintain a Higher High-Higher Low (HH-HL) formation, reflecting sustained buying interest and a healthy continuation of the prevailing uptrend. After witnessing a recent retracement, the stock has taken support near its 50-Day EMA and resumed its upward move, indicating strong demand at lower levels. The latest price action shows 4.42% gains over the past week, reinforcing the bullish momentum in the stock.
As per the latest consolidated financials, Aurobindo Pharma demonstrated strong cost management with interest expenses accounting for only 1.14% of operating revenues and employee costs at 15.42% in FY26. The company's EBIT margin stood at 16.20% while net profit margin was 12.88%, indicating healthy profitability levels. The basic earnings per share (EPS) reached ₹15.67 for the quarter, reflecting the company's strong operational performance and ability to convert revenue into bottom-line growth.
According to The Economic Times, derivatives data reflects a positive undertone with supportive put writing activity. This derivatives positioning suggests that market participants are positioning for potential upside in the stock. The supportive put writing activity indicates confidence in the stock's ability to maintain its upward trajectory and provides a bullish backdrop for the recommended trading strategy. With the stock's recent strong performance and positive technical indicators, the derivatives market continues to support the bullish outlook.
As reported by The Economic Times, a bullish call ratio spread strategy is recommended for potential upside in Aurobindo Pharma. The recommendation is based on the stock's strong technical structure, positive momentum indicators, and supportive derivatives positioning. The strategy capitalizes on the stock's bullish technical formation, strong quarterly results, and the positive market sentiment reflected in the derivatives data. With the stock trading near its 52-week high of ₹1,636.80 and showing consistent technical strength, the bullish call spread strategy appears well-positioned for continued upward movement.
